Get to know our clinical trials
Clinical trial of an amikacin liposome inhalation suspension-based regimen in patients with pulmonary mycobacterial infection
THE ENCORE TRIAL IS A PHASE IIIB STUDY TO EVALUATE THE EFFICACY OF ALIS AZITHROMYCIN (AZI) ETHAMBUTOL (ETH) COMPARED TO THE EMPTY LIPOSOME CONTROL (VLC) AZI ETH ON PATIENT-REPORTED RESPIRATORY SYMPTOMS AT MONTH 13. ALIS (AMIKACIN LIPOSOME INHALATION SUSPENSION) 590 MG OR PLACEBO (VLC) IS ADMINISTERED BY INHALATION VIA A NEBULIZER DEVICE (EFLOW®), ONCE DAILY. AZI 250 MG AND ETH 15 MG/KG TABLETS ARE TO BE TAKEN ORALLY ONCE DAILY. THE PURPOSE IS TO EVALUATE THE EFFECT AND SAFETY OF TREATMENT WITH INHALED LIPOSOMAL AMIKACIN SUSPENSION (ALIS) WHEN ADMINISTERED TO PATIENTS WHO HAVE A NEW DIAGNOSIS OF MNT LUNG INFECTION CAUSED BY MAC AND WHO HAVE NOT YET STARTED TREATMENT.
- ENCORE - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE TREATMENT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) BASED REGIMEN IN ADULT PATIENTS WITH NEWLY DIAGNOSED PULMONARY NONTUBERCULOUS MYCOBACTERIAL INFECTION (NTM) CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC).
- Code EudraCT: 2020-003079-16
- Protocol number: INS-416
- Promoter: Insmed Incorporated
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.